公开(公告)号：US20190105372A1

公开(公告)日：2019-04-11

申请号：US16218016

申请日：2018-12-12

申请人： RETINAL SOLUTIONS LLC

发明人： Michael T. Trese ,  Antonio Capone ,  Kimberly Drenser

IPC分类号： A61K38/17 ,  A61K38/18 ,  A61P9/10 ,  A61P7/10 ,  A61P1/00

CPC分类号： A61K38/1709 ,  A61K38/1891 ,  A61P1/00 ,  A61P7/10 ,  A61P9/10 ,  A61P29/00 ,  C07K14/515 ,  C07K14/75

摘要： A method of tightening inter-cellular junctions in endothelial or epithelial cells includes exposing the endothelial or epithelial cells to a norrin in concert with an anti-VEGF agent. Upon sufficient contact time, for norrin to selectively up-regulate gene expression of Cadherin or claudin-5 in the endothelial or epithelial cells, the inter-cellular junctions are tightened.

公开(公告)号：US20180355019A1

公开(公告)日：2018-12-13

申请号：US15971700

申请日：2018-05-04

申请人： Mosaic Biosciences, Inc.

发明人： Alexei KAZANTSEV ,  Peter D. MARINER ,  Martin STANTON

IPC分类号： C07K14/75 ,  A61K47/54 ,  A61K47/60 ,  C07K1/107 ,  C12N9/96 ,  C12N9/50

CPC分类号： C07K14/75 ,  A61K47/557 ,  A61K47/60 ,  C07K1/1077 ,  C12N9/63 ,  C12N9/96 ,  C12Y304/22006

摘要： The present disclosure provides a method of covalently modifying a biological macromolecule, the method comprising subjecting a reaction mixture comprising: (a) a biological macromolecule comprising one or more thiol groups; and (b) a molecule comprising one or more olefin or alkyne moieties to a radical reaction under conditions sufficient to produce the covalently modified biological macromolecule. The present disclosure also provides a method of covalently modifying a biological macromolecule, the method comprising subjecting a reaction mixture comprising: (a) a molecule comprising one or more thiol groups; and (b) a biological macromolecule comprising one or more olefin or alkyne moieties to a radical reaction under conditions sufficient to produce the covalently modified biological macromolecule. The present disclosure further provides a covalently modified biological macromolecule prepared by any of the disclosed methods. The covalently modified biological macromolecules may be further crosslinked to form a scaffold.

公开(公告)号：US20180306795A1

公开(公告)日：2018-10-25

申请号：US15768946

申请日：2016-10-14

申请人： Cizzle Biotechnology Limited

发明人： Dawn Alison Coverley

IPC分类号： G01N33/574 ,  C07K14/75 ,  A61K38/36 ,  G01N33/50

CPC分类号： G01N33/57423 ,  A21D8/04 ,  A61K38/363 ,  C07K14/75 ,  C12N9/2414 ,  C12Y302/01133 ,  G01N33/5076 ,  G01N33/574

摘要： The present invention relates to the use of a fibrinogen capture agent or a fibrinogen detection agent in an assay to detect a Ciz1 b-variant.

公开(公告)号：US09938318B2

公开(公告)日：2018-04-10

申请号：US15164736

申请日：2016-05-25

申请人： OCTAPHARMA AG

发明人： Petra Schulz ,  Rainer Pape ,  Werner Gehringer

IPC分类号： C07K14/75 ,  C07K1/18 ,  C07K1/36

CPC分类号： C07K1/18 ,  C07K1/36 ,  C07K14/75

摘要： The present invention relates to a method or process for the manufacture of a virus and prion save native fibrinogen concentrate of high purity and low amounts of fibrinopeptide A and fibronectin.

公开(公告)号：US09815874B2

公开(公告)日：2017-11-14

申请号：US15011738

申请日：2016-02-01

申请人： Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. ,  CollPlant Ltd.

发明人： Oded Shoseyov ,  Shaul Lapidot ,  Sigal Meirovitch ,  Daniel L. Siegel

IPC分类号： C08L89/00 ,  C08B15/06 ,  C07K14/435 ,  C12N15/82 ,  C08B15/00 ,  C07K17/10 ,  C07K14/75 ,  B01J19/12 ,  A61K31/717 ,  A61K38/17

CPC分类号： C07K14/43581 ,  A61K31/717 ,  A61K38/1767 ,  B01J19/127 ,  B01J2219/1203 ,  C07K14/43518 ,  C07K14/43563 ,  C07K14/43586 ,  C07K14/43595 ,  C07K14/75 ,  C07K17/10 ,  C07K2319/20 ,  C08B15/005 ,  C08B15/06 ,  C08L89/00 ,  C12N15/8257

摘要： Isolated polypeptides are disclosed comprising an amino acid sequence encoding a monomer of a fibrous polypeptide attached to a heterologous polysaccharide binding domain. Composites comprising same, methods of generating same and uses thereof are all disclosed.

公开(公告)号：US20170282095A1

公开(公告)日：2017-10-05

申请号：US15451743

申请日：2017-03-07

申请人： Therapure Biopharma Inc.

发明人： Allan Otto Fog Lihme

IPC分类号： B01D15/08 ,  B01D15/42 ,  C07K16/00 ,  C07K14/755 ,  C07K14/81 ,  B01D15/20 ,  C07K1/16

CPC分类号： B01D15/08 ,  B01D15/206 ,  B01D15/424 ,  C07K1/16 ,  C07K14/47 ,  C07K14/75 ,  C07K14/755 ,  C07K14/76 ,  C07K14/79 ,  C07K14/81 ,  C07K16/00

摘要： The present invention provides a process for the isolation of one or more proteins) from a protein solution. The process comprising the steps of: a) providing a protein solution comprising one or more specific proteins) and having a preset pH and a preset ionic strength or conductivity, b) applying the protein solution to a packed bed or expanded bed column comprising an adsorbent, and c) obtaining one or more proteins) from the column; wherein the protein solution has been supplemented with an alcohol.

公开(公告)号：US20170266322A1

公开(公告)日：2017-09-21

申请号：US15614597

申请日：2017-06-05

申请人： The J. David Gladstone Institutes, a testamentary established under the Will of J. David Glads

发明人： Katerina Akassoglou ,  Jae Kyu Ryu

IPC分类号： A61K49/00 ,  A01K67/027 ,  C07K14/75

CPC分类号： A61K49/0008 ,  A01K67/027 ,  A01K2207/10 ,  A01K2227/105 ,  A01K2267/0318 ,  A01K2267/035 ,  C07K14/75

摘要： The present invention provides non-human animal models of neuronal injury and/or cognitive dysfunction and methods of making and using such animal models. The animal models of the invention are particularly suited to assessing neurodegeneration in selected regions of interest in the CNS, and thus especially useful for testing the therapeutic efficacy of agents targeting neurodegeneration associated with aging, neurodegenerative diseases, autoimmunity and trauma (e.g., ischemia).

公开(公告)号：US20170218011A1

公开(公告)日：2017-08-03

申请号：US15455956

申请日：2017-03-10

申请人： AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

发明人： Peter Stanley Gagnon

IPC分类号： C07K1/16 ,  C12N7/00 ,  B01D15/36 ,  C07K14/75 ,  B01D15/34 ,  C07K16/00 ,  C07K14/755

CPC分类号： C07K14/75 ,  B01D15/08 ,  B01D15/166 ,  B01D15/1807 ,  B01D15/34 ,  B01D15/363 ,  B01D15/3885 ,  C07K1/16 ,  C07K14/755 ,  C07K16/00 ,  C07K16/065 ,  C12N7/00 ,  C12N2795/00 ,  C12N2795/14151

摘要： Materials and methods for use of constrained cohydration agents in the purification of biological materials such as antibodies, viruses, cells, and cellular organelles in connection with convective chromatography, fluidized bed or co-precipitation applications.

公开(公告)号：US09700600B2

公开(公告)日：2017-07-11

申请号：US14840084

申请日：2015-08-31

申请人： Regentis Biomaterials Ltd.

发明人： Dror Seliktar ,  Liora Almany

IPC分类号： A61K38/36 ,  A61K47/48 ,  A61L24/10 ,  A61L27/18 ,  A61L27/22 ,  A61L27/24 ,  A61L27/38 ,  A61L27/52 ,  C07K14/75 ,  C12N5/00 ,  A61K9/00 ,  A61K9/06 ,  A61K35/34 ,  A61K38/00

CPC分类号： A61K38/363 ,  A61K9/0024 ,  A61K9/06 ,  A61K35/34 ,  A61K38/00 ,  A61K47/60 ,  A61K47/6435 ,  A61K47/6903 ,  A61L24/106 ,  A61L27/18 ,  A61L27/225 ,  A61L27/227 ,  A61L27/24 ,  A61L27/38 ,  A61L27/52 ,  C07K14/75 ,  C12N5/0068 ,  C12N2533/30 ,  C12N2533/40 ,  C12N2533/50 ,  C12N2533/52 ,  C12N2533/54 ,  C08L71/02

摘要： A method of treating a disorder characterized by tissue damage is provided. The method comprising providing to a subject in need-thereof a composition which comprises a synthetic polymer attached to denatured fibrinogen or a therapeutic portion of the fibrinogen, the composition being formulated for releasing the therapeutic portion of the fibrinogen in a pharmacokinetically regulated manner, thereby treating the disorder characterized by tissue damage or malformation.

公开(公告)号：US09694054B2

公开(公告)日：2017-07-04

申请号：US14877354

申请日：2015-10-07

申请人： Mallinckrodt Pharma IP Trading D.A.C.

发明人： Joseph Grimbergen ,  Jacob Koopman ,  Abraham Bout

IPC分类号： C12Q1/56 ,  C12P21/04 ,  A61K38/00 ,  C07K14/75 ,  A61K38/36 ,  C12P21/00

CPC分类号： A61K38/363 ,  A61K38/4833 ,  C07K14/75 ,  C12P21/005 ,  A61K2300/00

摘要： The present invention relates to fibrinogen preparations enriched in α-extended fibrinogen. Compositions comprising such preparations show improved clotting properties compared to preparations based on HMW Fib which typically contain no or only low amounts of α-extended fibrinogen. In particular, clot formation time and the clot strength of a clot made by α-extended fibrinogen are improved. In addition, plasmin-mediated degradation of α-extended fibrinogen is reduced as compared to plasma derived fibrinogen.